Immunology
NIH adds long-acting antibody COVID-19 therapy to ACTIV-3 master protocol
The National Institutes of Health (NIH) has begun a new arm of its master protocol, the Accelerating COVID-19 Therapeutic Interventions and Vaccines 3 (ACTIV-3) study, which evaluates the safety and efficacy of an investigational long-acting antibody combination for the treatment of patients hospitalized with COVID-19. Read More
COVID-19 vaccines may be causing orofacial reactions
The two COVID-19 vaccines being given to patients in the U.S. and other countries have been linked to orofacial adverse drug reactions such as temporary facial paralysis, according to a brief report published on February 1 in the Journal of Oral Pathology & Medicine. Read More
Deep-learning approach points the way to faster COVID-19 vaccines
A novel deep neural network can target the most promising multiepitope COVID-19 vaccine candidates in a matter of seconds. The new artificial intelligence framework, which was described in Scientific Reports on February 5, may give scientists an edge in the race against SARS-CoV-2 and its variants by reducing the time from vaccine design to clinical trials. Read More
New COVID-19 vaccine platforms emerge, are effective in preclinical models
Additional vaccine approaches are necessary to fight COVID-19. Two new vaccine candidates have demonstrated their effectiveness in animal models, and their potential clinical applications are described in two new research studies. Read More
Recurrent deletions help SARS-CoV-2 mutate to escape antibodies
Researchers have identified a pattern of deletions in the spike glycoprotein of the SARS-CoV-2 virus that can prevent antibody binding, which is part of the body's immune response to a foreign virus. These deletions occur as a recurring pattern of evolution, according to a study published in Science on February 3. Read More
Researchers innovate drug discovery screening techniques
Researchers from around the globe gathered to discuss innovations in laboratory techniques such as phenotypic profiling and flow cytometry for drug discovery applications at the Society for Laboratory Automation and Screening 2021 virtual meeting. Read More
Acute SARS-CoV-2 infection elicits distinct antibody, T-cell responses
An analysis of antibody and T-cell responses during the entire timeline of SARS-CoV-2 infection reveals the different ways the immune system responds to the virus in the early phases of COVID-19 disease. The results, published in Cell Reports on January 21, suggest that T-cell responses may be important for controlling infection while antibodies provide longer protection. Read More
Protein biosensors show promise for SARS-CoV-2 testing
Scientists have developed biosensors to detect SARS-CoV-2 proteins and antibodies in simulated nasal fluids and human sera, according to a study published in Nature on January 27. The approach promises to be less costly and time-consuming than current COVID-19 testing methods. Read More
SARS-CoV-2 mutation doesn't affect viral spread, but may limit therapies
As SARS-CoV-2 spreads around the globe, mutations of the virus are inevitable. An international team of researchers sought to define the effects of a specific receptor-binding motif mutation on viral fitness, clinical outcomes, and resistance to therapeutic antibodies. The findings of the study were published on January 28 in Cell. Read More
2003 SARS-CoV antibodies may provide some protection from SARS-CoV-2
A new study shows that antibodies against the original 2003 SARS-CoV also react with the current SARS-CoV-2 strain, but only with limited effectiveness. The findings were published in Cell Reports on January 25. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter